Aliases & Classifications for Rosacea

MalaCards integrated aliases for Rosacea:

Name: Rosacea 12 43 42 44 15 62 17 70 32
Erythematotelangiectatic Rosacea 43
Papulopustular Rosacea 43
Granulomatous Rosacea 43
Acne, Erythematosa 12
Phymatous Rosacea 43
Ocular Rosacea 43
Acne Roscea 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8881
ICD9CM 34 695.3
MeSH 44 D012393
NCIt 50 C97136
SNOMED-CT 67 1612004
ICD10 32 L71 L71.9
UMLS 70 C0035854

Summaries for Rosacea

MedlinePlus Genetics : 43 Rosacea is a long-lasting (chronic) skin disease that affects the face, primarily the forehead, nose, cheeks, and chin. The signs and symptoms of rosacea vary, and they may come and go or change over time.There are three main types of rosacea, categorized by their primary signs and symptoms. Erythematotelangiectatic rosacea causes skin redness and warmth (flushing) and visible clusters of blood vessels (telangiectasia). Papulopustular rosacea causes skin redness, swelling, and pus-filled bumps called pustules. Phymatous rosacea is characterized by thickened skin on the face and an enlarged, bulbous nose (rhinophyma). People with rosacea may feel itching, stinging, or burning sensations in affected areas. Often, the disorder affects the eyes, causing abnormal inflammation of the eyelids and eyes (ocular rosacea). This inflammation can cause dryness, redness, and irritation of the eyes and may affect vision.

MalaCards based summary : Rosacea, also known as erythematotelangiectatic rosacea, is related to blepharitis and acne, and has symptoms including pruritus and exanthema. An important gene associated with Rosacea is CAMP (Cathelicidin Antimicrobial Peptide), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Azelaic acid and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and pituitary, and related phenotypes are homeostasis/metabolism and hematopoietic system

MedlinePlus : 42 Rosacea is a long-term disease that affects your skin and sometimes your eyes. It causes redness and pimples. Rosacea is most common in women and people with fair skin. It most often affects middle-aged and older adults. In most cases, rosacea only affects the face. Symptoms can include Frequent redness of the face, or flushing Small, red lines under the skin Acne A swollen nose Thick skin, usually on the forehead, chin, and cheeks Red, dry, itchy eyes and sometimes vision problems No one knows what causes rosacea. You may be more likely to have it if you blush a lot or if rosacea runs in your family. Rosacea is not dangerous. There is no cure, but treatments can help. They include medicines and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

PubMed Health : 62 About rosacea: Red patches of skin on your face, and tiny visible blood vessels and spots – these can be quite common symptoms. They may be caused by rosacea, a common facial skin inflammation. Skin diseases can be difficult to cope with, and they often affect people’s self-confidence and wellbeing. But if you have rosacea, there is a lot you can do on your own.

Wikipedia : 73 Rosacea is a long-term skin condition that typically affects the face. It results in redness, pimples,... more...

Related Diseases for Rosacea

Diseases related to Rosacea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
# Related Disease Score Top Affiliating Genes
1 blepharitis 31.8 TNF STAT1 MMP9 CXCL8
2 acne 31.6 VDR TNF TLR2 IL6 CXCL8
3 pustulosis of palm and sole 30.7 TNF IL17A CXCL8 CRP
4 pyoderma 30.6 TNF MMP9 CXCL8 CRP
5 keratitis, hereditary 30.6 VEGFA TNF TLR2 MMP9 IL6 IL17A
6 hidradenitis 30.5 TNF IL17A CAMP
7 hidradenitis suppurativa 30.5 TNF IL17A CAMP
8 keratoconjunctivitis 30.5 TNF MMP9 IL6 IL17A CXCL8
9 lichen planus 30.5 TNF IL6 IL17A CXCL8
10 sarcoidosis 1 30.4 TNF STAT1 IL18 CRP
11 conjunctivitis 30.4 TNF MMP9 IL6 IL33 CXCL8
12 exanthem 30.4 VEGFA TNF IL6 IL18 CXCL8 CRP
13 skin disease 30.4 VEGFA VDR TNF TLR2 IL6 IL18
14 ulcerative colitis 30.3 TNF IL6 IL17A CXCL8 CRP
15 irritable bowel syndrome 30.3 TNF IL6 CXCL8 CRP
16 purpura 30.3 TNF IL6 CRP
17 migraine with or without aura 1 30.2 TNF IL6 GSTM1 CRP
18 cutaneous lupus erythematosus 30.2 TNF IL6 IL18 IL17A
19 peptic ulcer disease 30.2 TNF S100A8 CXCL8
20 chronic urticaria 30.2 TNF IL6 CRP
21 gastroesophageal reflux 30.2 TNF S100A8 IL6 CXCL8
22 gastritis 30.1 TNF S100A8 IL6 IL17A CXCL8
23 allergic contact dermatitis 30.1 TNF IL6 IL33 IL17A CXCL8
24 neutrophilic dermatosis, acute febrile 30.1 TNF CXCL8 CRP
25 mental depression 30.1 TNF IL6 CRP
26 venous insufficiency 30.1 VEGFA MMP9 CRP
27 dermatitis 30.1 TNF TLR2 STAT1 IL6 IL33 IL18
28 urticaria 30.1 TNF IL6 IL18 CXCL8 CRP
29 acquired immunodeficiency syndrome 30.1 TNF IL6 GSTM1 CRP
30 syphilis 30.1 TNF IL6 IL17A CRP
31 dry eye syndrome 30.0 TNF S100A8 IL6
32 fungal keratitis 30.0 TLR2 MMP9 MMP8
33 trichomoniasis 30.0 TNF IL6 CXCL8
34 colitis 30.0 TNF TLR2 IL6 IL18 IL17A CXCL8
35 contact dermatitis 30.0 TNF TLR2 IL6 IL33 IL18 IL17A
36 pyoderma gangrenosum 30.0 TNF MMP9 CXCL8
37 chlamydia pneumonia 30.0 TNF TLR2 IL6 CXCL8 CRP
38 vasculitis 30.0 TNF IL6 IL17A CRP
39 keratoconus 30.0 TNF MMP9 MMP3 IL6
40 dermatitis herpetiformis 29.9 TNF IL17A CXCL8
41 thyroiditis 29.9 TNF IL6 IL17A CRP
42 chronic venous insufficiency 29.9 VEGFA MMP9 CRP
43 erysipelas 29.9 TNF IL6 CRP
44 nasopharyngitis 29.9 TNF IL17A CRP
45 trachoma 29.8 VEGFA TNF IL6 IL17A
46 leishmaniasis 29.8 TNF TLR2 IL6 IL17A
47 dermatitis, atopic 29.8 TNF TLR2 IL6 IL33 IL18 IL17A
48 uveitis 29.8 TNF IL6 IL17A CXCL8
49 hypopyon 29.8 VEGFA TNF IL6 IL17A CRP
50 cellulitis 29.8 TNF IL6 CRP CAMP

Graphical network of the top 20 diseases related to Rosacea:



Diseases related to Rosacea

Symptoms & Phenotypes for Rosacea

UMLS symptoms related to Rosacea:


pruritus; exanthema

MGI Mouse Phenotypes related to Rosacea:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ADAMDEC1 CRP IL17A IL18 IL33 IL6
2 hematopoietic system MP:0005397 10.33 ADAMDEC1 CAMP IL17A IL18 IL33 IL6
3 immune system MP:0005387 10.33 ADAMDEC1 CAMP CRP IL17A IL18 IL33
4 cellular MP:0005384 10.29 CAMP IL18 IL33 IL6 IRF4 KDR
5 growth/size/body region MP:0005378 10.29 ADAMDEC1 IL17A IL18 IL33 IL6 IRF4
6 cardiovascular system MP:0005385 10.26 CRP IL18 IL6 KDR MMP8 MMP9
7 digestive/alimentary MP:0005381 10.24 ADAMDEC1 IL17A IL18 IL33 IL6 MMP9
8 mortality/aging MP:0010768 10.17 ADAMDEC1 CAMP IL17A IL18 IL33 IL6
9 integument MP:0010771 10.11 IL17A IL18 IL33 IL6 KDR MMP9
10 muscle MP:0005369 9.91 IL18 IL6 KDR MMP9 STAT1 TLR2
11 neoplasm MP:0002006 9.76 IL6 IRF4 MMP8 MMP9 STAT1 TLR2
12 respiratory system MP:0005388 9.61 IL17A IL33 IL6 KDR MMP9 STAT1
13 skeleton MP:0005390 9.36 IL17A IL33 IL6 KDR MMP3 MMP9

Drugs & Therapeutics for Rosacea

PubMed Health treatment related to Rosacea: 62

There are a lot of creams, lotions and gels recommended for the treatment of rosacea . Creams and gels with either azelaic acid or the antibiotic metronidazole in them are used most commonly. Antibiotics can also be taken as tablets, but then the entire body is affected.

Drugs for Rosacea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azelaic acid Approved Phase 4 123-99-9 2266
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
Metronidazole Approved Phase 4 443-48-1 4173
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
6
Sarecycline Approved, Investigational Phase 4 1035654-66-0
7
Sulfacetamide Approved Phase 4 144-80-9 5320
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Phenylephrine Approved Phase 4 59-42-7 6041
10
Pseudoephedrine Approved Phase 4 90-82-4 7028
11
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
12 Dermatologic Agents Phase 4
13 Antimalarials Phase 4
14 Antiparasitic Agents Phase 4
15 Anti-Bacterial Agents Phase 4
16 Anti-Infective Agents Phase 4
17 Antiprotozoal Agents Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Antirheumatic Agents Phase 4
20 Adrenergic alpha-Agonists Phase 4
21 Adrenergic Agents Phase 4
22 Neurotransmitter Agents Phase 4
23 Adrenergic Agonists Phase 4
24 Cyclosporins Phase 4
25 Immunosuppressive Agents Phase 4
26 Immunologic Factors Phase 4
27 Calcineurin Inhibitors Phase 4
28 Antifungal Agents Phase 4
29 Brimonidine Tartrate Phase 4 70359-46-5
30 Antihypertensive Agents Phase 4
31 Vasoconstrictor Agents Phase 4
32 Cardiotonic Agents Phase 4
33 Respiratory System Agents Phase 4
34 Mydriatics Phase 4
35 Sympathomimetics Phase 4
36 Protective Agents Phase 4
37 Nasal Decongestants Phase 4
38
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
39
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
40
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
41
tannic acid Approved Phase 3 1401-55-4
42
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
43
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
44 Clindamycin phosphate Phase 2, Phase 3
45 Clindamycin palmitate Phase 2, Phase 3
46 Clindamycin, tretinoin drug combination Phase 2, Phase 3
47 Sunscreening Agents Phase 3
48 Radiation-Protective Agents Phase 3
49 Keratolytic Agents Phase 3
50
Lactulose Approved Phase 2 4618-18-2 11333

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Papulopustular Rosacea Unknown status NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
2 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea- a Prospective Study Unknown status NCT03053700 Phase 4 Bromonide 0.33% gel
3 A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules Completed NCT01308619 Phase 4 Doxycycline
4 A Multicenter, Double-Blind Clinical Trial to Assess the Efficacy and Tolerability of Topical Azelaic Acid 15% Gel Once Daily Compared to Topical Azelaic Acid 15% gelTwice Daily in Subjects With Papulopustular Rosacea Completed NCT00417937 Phase 4 azelaic acid 15% gel;azelaic acid 15% gel
5 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Completed NCT01872715 Phase 4 Oracea
6 An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily in Subjects With Moderate Papulopustular Rosacea Completed NCT00855595 Phase 4 Azelaic acid (Finacea, BAY39-6251);Metronidazole (Metrogel);Doxycycline (Oracea)
7 Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea Completed NCT00348335 Phase 4 Cyclosporine 0.05%;Ocular lubricant
8 Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea Completed NCT03048058 Phase 4 brimonidine topical gel 0.33% & survey;brimonidine topical gel 0.33% & SOC
9 Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence Completed NCT03418610 Phase 4 Azelaic Acid foam 15%
10 Determine the Effects of COL-101 Administered Once Daily With Metronidazole Topical Gel, 1% Versus Doxycycline Hyclate 100 mg Administered Once Daily With Metronidazole Topical Gel, 1% in Patients With Moderate to Severe Rosacea Completed NCT00495313 Phase 4 doxycycline;doxycycline
11 Efficacy Comparison of Ivermectin 1% Topical Cream Associated With Doxycycline 40 mg Modified Release (MR) Capsules Versus Ivermectin 1% Topical Cream Associated With Placebo in the Treatment of Severe Rosacea Completed NCT03075891 Phase 4 Ivermectin 1% cream;Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
12 MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study) Completed NCT02249065 Phase 4 Brimonidine
13 A Pilot Study on the Use of Seysara for Rosacea Completed NCT04555525 Phase 4 sarecycline
14 Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea Completed NCT02616250 Phase 4 Brimonidine 0.33% gel (Br);Ivermectin 1% cream (IVM)
15 Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea Completed NCT03380390 Phase 4 Oxymetazoline HCL 1.0% Cream
16 Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Completed NCT02147691 Phase 4 Azelaic acid 15%;Brimonidine 0.33%
17 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea Completed NCT01426269 Phase 4 Doxycycline;Metronidazole;Placebo
18 A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea Completed NCT00892281 Phase 4 doxycycline (Oracea®) 40 mg modified release as monotherapy;doxycycline (Oracea®) 40 mg modified release as add-on therapy
19 MetroGel 1% Hydration Study: A Kinetic Regression Study Completed NCT00436527 Phase 4 Metronidazole gel 1%
20 Pilot Study to Evaluate Vbeam® Prima Pulsed Dye Laser (PDL) Treatment and RHOFADE® (Oxymetazoline HCL, 1% Cream) for Erythematotelangiectatic Rosacea Recruiting NCT04153188 Phase 4 Oxymetazoline HCL 1% Cream
21 a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis Unknown status NCT02036229 Phase 3 ivermectin cream 0.5%
22 A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Completed NCT03564119 Phase 3 S5G4T-1;S5G4T-2
23 A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Completed NCT03448939 Phase 3 S5G4T-1;S5G4T-2
24 A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea Completed NCT00126399 Phase 3 doxycycline
25 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
26 A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks Completed NCT00823901 Phase 2, Phase 3 Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel;Placebo gel
27 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
28 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea Completed NCT02840461 Phase 3 Ivermectin Cream, 1%;Placebo/Vehicle cream
29 A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Completed NCT01494467 Phase 3 CD5024;Azelaic acid 15% Gel
30 Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period. Completed NCT01493947 Phase 3 Ivermectin 1% cream;Metronidazole 0.75% cream
31 A Multi Center, Open Label, Long Term Study of S5G4T-1 to Evaluate the Safety of S5G4T-1 in Papulopustular Rosacea Patients Completed NCT03564145 Phase 3 S5G4T-1
32 A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11) Completed NCT03142451 Phase 3 FMX103 minocycline foam 1.5%;Vehicle foam
33 A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Completed NCT01493687 Phase 3 CD5024;Azelaic acid 15% Gel
34 A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-12) Completed NCT04608500 Phase 3 FMX103 minocycline foam 1.5%;Vehicle foam
35 A Multi-center, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Metronidazole Gel 1%, to Metrogel® (Metronidazole Gel) 1% in the Treatment of Rosacea Completed NCT02393937 Phase 3 Reference: Metronidazole Gel 1%;Test: Metronidazole Gel 1%;Placebo Gel
36 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea Completed NCT01555463 Phase 3 Azelaic acid foam, 15% (BAY39-6251);Vehicle foam
37 An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13) Completed NCT03276936 Phase 3 FMX103 1.5%
38 A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension Completed NCT02547441 Phase 3 CLS001 (Omiganan);Vehicle
39 The Effect of Azelaic Acid (Financea Gel 15%) on Demodex Folliculorum Counts in Adult Subjects With Mild to Moderate Papulopustular Rosacea Completed NCT03035955 Phase 2, Phase 3 Azelaic acid
40 A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period Completed NCT02576860 Phase 3 CLS001 (Omiganan);Vehicle
41 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Completed NCT02385240 Phase 3 Brimonidine Topical Gel, 0.33 percent (Perrigo);Brimonidine Topical Gel, 0.33 percent (Reference);Placebo gel
42 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
43 A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT02289352 Phase 3 Brimonidine;placebo
44 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea Completed NCT00041977 Phase 3 doxycycline hyclate 20 mg twice daily
45 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed NCT02795117 Phase 3 Ivermectin;Ivermectin (reference);Placebo
46 Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT03352323 Phase 3 Oxymetazoline
47 A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product "Oxymetazoline Hydrochloride Cream, 1%" to Reference Product "RHOFADETM Cream, 1%" in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea Completed NCT03954444 Phase 3 Oxymetazoline Hydrochloride;Rhofade Cream, 1%;Placebo
48 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Completed NCT02800148 Phase 3 Azelaic acid foam;Azelaic acid foam;Azelaic acid foam - Placebo
49 A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea Completed NCT02576847 Phase 3 Omiganan
50 A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (Azelaic Acid) Foam,15% in Patients With Moderate Facial Rosacea Completed NCT03287791 Phase 3 Generic Azelaic Acid Foam;Finacea® (Azelaic Acid) Foam;Vehicle Foam

Search NIH Clinical Center for Rosacea

Inferred drug relations via UMLS 70 / NDF-RT 51 :


azelaic acid
Benzoyl Peroxide
Colloid sulfur
Loteprednol
loteprednol etabonate
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
resorcinol
RESORCINOL PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL

Cochrane evidence based reviews: rosacea

Genetic Tests for Rosacea

Anatomical Context for Rosacea

MalaCards organs/tissues related to Rosacea:

40
Skin, Eye, Pituitary, Endothelial, Retina, Small Intestine, Colon

Publications for Rosacea

Articles related to Rosacea:

(show top 50) (show all 3342)
# Title Authors PMID Year
1
Inhibition of Hippo Signaling Improves Skin Lesions in a Rosacea-Like Mouse Model. 42 61
33477764 2021
2
Paeoniflorin inhibits the macrophage-related rosacea-like inflammatory reaction through the suppressor of cytokine signaling 3-apoptosis signal-regulating kinase 1-p38 pathway. 42 61
33545988 2021
3
Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology. 61 42
33172727 2020
4
Identification of novel candidate genes in rosacea by bioinformatic methods. 61
33529888 2021
5
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
6
Pediatric Demodicosis Associated with Gain-of-Function Variant in STAT1 Presenting as Rosacea-Type Rash. 61
33404972 2021
7
Successful Treatment of Corticosteroid-Induced Rosacea-Like Dermatitis with Platelet-Rich Plasma Mesotherapy: Report of Seven Cases. 61
33539001 2021
8
Paired Transcriptomic and Proteomic Analysis Implicates IL-1β in the Pathogenesis of Papulopustular Rosacea Explants. 61
32941918 2021
9
Acne in the first three decades of life: An update of a disorder with profound implications for all decades of life. 61
33041056 2021
10
Efficacy of non-ablative fractional 1440-nm laser therapy for treatment of facial acne scars in patients with rosacea: a prospective, interventional study. 61
32719961 2021
11
Efficacy and tolerability of a cream containing modified glutathione (GSH-C4), beta-Glycyrrhetic, and azelaic acids in mild-to-moderate rosacea: A pilot, assessor-blinded, VISIA and ANTERA 3-D analysis, two-center study (The "Rosazel" Trial). 61
32885541 2021
12
Childhood rosacea and related disorders. 61
33217048 2021
13
The Addition of Tissue Stromal Vascular Fraction To Platelet-Rich Plasma Supplemented Lipofilling Does Not Improve Facial Skin Quality: A Prospective Randomized Clinical Trial. 61
33687052 2021
14
Rosacea: New Concepts in Classification and Treatment. 61
33759078 2021
15
Characterization of rosacea in Chinese: An analysis of 254 cases. 61
33655687 2021
16
The effect of 577-nm pro-yellow laser on demodex density in patients with rosacea. 61
33742514 2021
17
COVID-19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi-center, real-life, telemedical, and observational prospective study. 61
33533563 2021
18
Ocular manifestations of rosacea: A clinical review. 61
33403718 2021
19
A Novel Convolutional Neural Network for the Diagnosis and Classification of Rosacea: Usability Study. 61
33720027 2021
20
[Granulomatous rosacea-like dermatitis under therapy with tofacitinib]. 61
33760960 2021
21
Mask-induced Koebner phenomenon and its clinical phenotypes: A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics. 61
33527560 2021
22
"Fake news" in dermatology. Results from an observational, cross-sectional study. 61
33095467 2021
23
Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease - Population-Based Case-control and Cohort analyses. 61
33730366 2021
24
The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. 61
33810197 2021
25
Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study. 61
33280139 2021
26
Topical Corticosteroids: Choice and Application. 61
33719380 2021
27
Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic: Insights from Google Trends. 61
33595849 2021
28
From Dysbiosis to Healthy Skin: Major Contributions of Cutibacterium acnes to Skin Homeostasis. 61
33803499 2021
29
Rosacea, Germs, and Bowels: A Review on Gastrointestinal Comorbidities and Gut-Skin Axis of Rosacea. 61
33507499 2021
30
Systemic Conditions Associated with Severity of Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study. 61
33785415 2021
31
Safety and Efficacy of an Augmented Intense Pulse Light Protocol for Dry Eye Syndrome and Blepharitis. 61
33370543 2021
32
Difference in vasoconstrictors: oxymetazoline vs. brimonidine. 61
31294643 2021
33
Risk factors for frontal fibrosing alopecia: A case-control study in a multiracial population. 61
32835739 2021
34
Readability, quality, and timeliness of online health resources for rosacea. 61
32857386 2021
35
Myeloid differentiation factor 88 expression in eyelid specimens of rosacea. 61
33789561 2021
36
Association between rosacea and smoking: A systematic review and meta-analysis. 61
33406295 2021
37
Radiofrequency Irradiation Modulates TRPV1-Related Burning Sensation in Rosacea. 61
33800730 2021
38
Rosacea with persistent facial erythema and high Demodex density effectively treated with topical ivermectin alone or combined with oral carvedilol. 61
33605018 2021
39
A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea. 61
33734592 2021
40
Evaluation of fecal calprotectin as a marker of gastrointestinal inflammation in rosacea: A case-control study. 61
33719160 2021
41
Emerging topical drugs for the treatment of rosacea. 61
33596752 2021
42
ANTIMICROBIAL PEPTIDE LL-37 DRIVES ROSACEA-LIKE SKIN INFLAMMATION IN AN NLRP3-DEPENDENT MANNER. 61
33745908 2021
43
Aspirin alleviates skin inflammation and angiogenesis in rosacea. 61
33743316 2021
44
Prevalence and risk factors for chalazion in an older veteran population. 61
33789846 2021
45
Radiofrequency Microneedling: A Comprehensive and Critical Review. 61
33577211 2021
46
Experience in managing glaucoma filtration surgery complications with oral doxycycline: A case series. 61
33550831 2021
47
Rosacea associated with dupilumab therapy. 61
31132923 2021
48
Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. 61
33600826 2021
49
Rosacea and the Microbiome: A Systematic Review. 61
33170492 2021
50
Impact of ultraviolet radiation and exposome on rosacea: Key role of photoprotection in optimizing treatment. 61
33626227 2021

Variations for Rosacea

Expression for Rosacea

Search GEO for disease gene expression data for Rosacea.

Pathways for Rosacea

Pathways related to Rosacea according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 VEGFA TNF TLR2 STAT1 S100A8 MMP9
2
Show member pathways
13.58 VEGFA TNF STAT1 KDR IL6 IL18
3
Show member pathways
13.44 TNF TLR2 STAT1 KDR IL6 IL18
4
Show member pathways
13.35 VEGFA TNF STAT1 MMP9 MMP3 IRF4
5
Show member pathways
13.22 TNF TLR2 STAT1 MMP9 MMP3 IL6
6
Show member pathways
13.03 VEGFA TNF TLR2 STAT1 KDR IL6
7
Show member pathways
12.97 VEGFA TNF TLR2 STAT1 IL6 CXCL8
8
Show member pathways
12.88 VEGFA TNF STAT1 IL6 IL17A CXCL8
9 12.87 VEGFA STAT1 MMP9 IL6 GSTM1 CXCL8
10
Show member pathways
12.86 TNF TLR2 STAT1 IL6 IL33 IL18
11
Show member pathways
12.77 TNF TLR2 IL6 IL18 CXCL8
12
Show member pathways
12.76 TNF TLR2 STAT1 IL6 IL33 IL18
13
Show member pathways
12.65 TNF TLR2 STAT1 IRF4 IL6 IL18
14
Show member pathways
12.64 TNF TLR2 STAT1 IRF4 IL6 IL17A
15
Show member pathways
12.63 TNF STAT1 IL6 IL18 IL17A
16 12.6 TNF TLR2 STAT1 IRF4 IL17A
17
Show member pathways
12.36 TNF IL6 IL18 CXCL8
18 12.34 VEGFA TNF TLR2 MMP9 KDR
19 12.3 MMP9 MMP3 IL6 CXCL8
20
Show member pathways
12.3 TNF TLR2 IL6 CXCL8
21 12.28 TNF STAT1 IL6 IL18 CXCL8 CAMP
22
Show member pathways
12.24 TNF STAT1 KDR IRF4 IL6 IL18
23
Show member pathways
12.23 TNF TLR2 STAT1 IL6 CXCL8
24 12.23 VEGFA TNF TLR2 STAT1 MMP9 IL6
25 12.22 VEGFA TNF IL6 CXCL8
26 12.2 VDR TNF TLR2 STAT1 IL6 IL18
27 12.14 VEGFA TNF MMP9 KDR GSTM1
28 12.12 TNF IL6 IL18 CXCL8
29
Show member pathways
12.09 TNF TLR2 S100A8 MMP9 MMP3 IL6
30 12.05 TNF MMP9 IL6 CXCL8
31 12.01 TNF MMP9 MMP3 IL6
32 11.97 TNF TLR2 IL6 CXCL8
33 11.97 VEGFA TNF STAT1 IL6 CXCL8
34
Show member pathways
11.95 TNF MMP9 MMP8 MMP3
35
Show member pathways
11.91 IRF4 IL6 IL17A CXCL8
36
Show member pathways
11.9 TLR2 STAT1 IL6 IL17A
37 11.86 TNF IRF4 IL33 IL18 IL17A
38 11.83 STAT1 IL6 CXCL8
39 11.79 TNF IL6 CXCL8
40
Show member pathways
11.79 TNF IRF4 CXCL8
41 11.78 TNF IRF4 IL6
42 11.77 VEGFA MMP9 CXCL8
43 11.72 TNF TLR2 IL6
44 11.72 TNF MMP9 IL6 CXCL8
45 11.71 MMP9 IL6 CXCL8
46 11.71 VEGFA STAT1 MMP9
47 11.68 MMP9 MMP3 CXCL8
48
Show member pathways
11.68 TNF TLR2 STAT1 IL6 IL18 IL17A
49 11.66 TNF TLR2 IL6 IL18 CXCL8
50 11.6 VEGFA IL6 CXCL8

GO Terms for Rosacea

Cellular components related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 VEGFA TNF S100A8 MMP9 MMP8 MMP3
2 extracellular region GO:0005576 9.5 VEGFA TNF S100A8 MMP9 MMP8 MMP3
3 tertiary granule lumen GO:1904724 9.33 MMP9 MMP8 CAMP

Biological processes related to Rosacea according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 VEGFA VDR TNF TLR2 STAT1 IRF4
2 neutrophil degranulation GO:0043312 10.09 TLR2 S100A8 MMP9 MMP8 CAMP
3 immune response GO:0006955 10.08 TNF TLR2 IL6 IL18 IL17A CXCL8
4 negative regulation of gene expression GO:0010629 10.02 VEGFA VDR TNF MMP8 KDR CXCL8
5 extracellular matrix organization GO:0030198 10.01 TNF MMP9 MMP8 MMP3 KDR
6 inflammatory response GO:0006954 10.01 TNF TLR2 S100A8 IL6 IL18 IL17A
7 positive regulation of protein phosphorylation GO:0001934 9.99 VEGFA TNF MMP9 KDR CAMP
8 cellular response to lipopolysaccharide GO:0071222 9.97 TNF IL6 CXCL8 CAMP
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.97 TNF TLR2 S100A8 IL6 IL18
10 defense response GO:0006952 9.95 TNF STAT1 CXCL8 CAMP
11 positive regulation of angiogenesis GO:0045766 9.95 VEGFA KDR CXCL8 CAMP
12 positive regulation of MAPK cascade GO:0043410 9.92 VEGFA MMP8 KDR IL6
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.9 VEGFA TNF KDR IL18
14 positive regulation of inflammatory response GO:0050729 9.89 TNF TLR2 S100A8 IL33 IL18
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 VEGFA TNF IL6 IL18
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR2 MMP8 IL18
17 positive regulation of tumor necrosis factor production GO:0032760 9.88 TLR2 MMP8 IL6 IL33 IL17A
18 cellular response to organic cyclic compound GO:0071407 9.87 TNF STAT1 IL18
19 extracellular matrix disassembly GO:0022617 9.86 MMP9 MMP8 MMP3
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 TNF STAT1 IL6 IL18
21 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR2 IL6
22 positive regulation of interleukin-1 beta production GO:0032731 9.85 TNF IL6 IL17A
23 positive regulation of protein complex assembly GO:0031334 9.85 VEGFA TNF MMP3
24 positive regulation of gene expression GO:0010628 9.85 VEGFA VDR TNF TLR2 MMP8 IL6
25 collagen catabolic process GO:0030574 9.82 MMP9 MMP8 MMP3
26 positive regulation of interleukin-10 production GO:0032733 9.81 TLR2 IRF4 IL6
27 positive regulation of chemokine production GO:0032722 9.81 TNF TLR2 IL6 IL33
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR2 IL18
29 defense response to Gram-positive bacterium GO:0050830 9.8 TNF TLR2 IL6 IL17A CRP CAMP
30 positive regulation of DNA binding GO:0043388 9.79 MMP9 MMP8 IRF4
31 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.78 TNF IL6 IL17A
32 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.73 TLR2 STAT1 KDR IL33
33 positive regulation of interleukin-6 production GO:0032755 9.73 TNF TLR2 MMP8 IL6 IL33 IL17A
34 cellular response to UV-A GO:0071492 9.7 MMP9 MMP3
35 positive regulation of interleukin-13 production GO:0032736 9.7 IRF4 IL33
36 response to molecule of bacterial origin GO:0002237 9.7 TLR2 CXCL8
37 negative regulation of lipid storage GO:0010888 9.7 TNF IL6 CRP
38 vascular wound healing GO:0061042 9.68 VEGFA KDR
39 T-helper 17 cell lineage commitment GO:0072540 9.68 IRF4 IL6
40 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
41 regulation of neuroinflammatory response GO:0150077 9.67 MMP9 MMP8 MMP3 IL6
42 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.66 VEGFA KDR
43 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.66 VEGFA KDR
44 chemokine production GO:0032602 9.65 S100A8 IL18
45 regulation of microglial cell activation GO:1903978 9.64 MMP8 IL6
46 positive regulation of neuroinflammatory response GO:0150078 9.35 TNF MMP8 IL6 IL33 IL18
47 cytokine-mediated signaling pathway GO:0019221 9.32 VEGFA TNF STAT1 MMP9 MMP3 IRF4

Molecular functions related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.73 VDR S100A8 MMP9 MMP8 MMP3 ADAMDEC1
2 metallopeptidase activity GO:0008237 9.46 MMP9 MMP8 MMP3 ADAMDEC1
3 metalloendopeptidase activity GO:0004222 9.26 MMP9 MMP8 MMP3 ADAMDEC1
4 cytokine activity GO:0005125 9.17 VEGFA TNF IL6 IL33 IL18 IL17A

Sources for Rosacea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....